Key stats
About iShares NASDAQ US Biotechnology UCITS ETF
Home page
Inception date
Oct 19, 2017
Structure
Irish VCIC
Replication method
Physical
Dividend treatment
Capitalizes
Primary advisor
BlackRock Asset Management Ireland Ltd.
ISIN
IE00BYXG2H39
The investment objective of the Fund is to seek to provide investors with a total return, taking into account both capital and income returns, which reflects the return of the NASDAQ Biotechnology Index.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks99.80%
Health Technology96.29%
Commercial Services1.47%
Technology Services1.25%
Health Services0.77%
Process Industries0.02%
Bonds, Cash & Other0.20%
Cash0.12%
Mutual fund0.08%
Miscellaneous0.00%
Stock breakdown by region
North America83.24%
Europe16.39%
Asia0.29%
Oceania0.07%
Latin America0.00%
Africa0.00%
Middle East0.00%
Top 10 holdings
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
A2DWAW invests in stocks. The fund's major sectors are Health Technology, with 96.29% stocks, and Commercial Services, with 1.47% of the basket. The assets are mostly located in the North America region.
A2DWAW top holdings are Gilead Sciences, Inc. and Vertex Pharmaceuticals Incorporated, occupying 7.80% and 7.75% of the portfolio correspondingly.
No, A2DWAW doesn't pay dividends to its holders.
A2DWAW shares are issued by BlackRock, Inc. under the brand iShares. The ETF was launched on Oct 19, 2017, and its management style is Passive.
A2DWAW expense ratio is 0.35% meaning you'd have to pay 0.35% of your investment to help manage the fund.
A2DWAW follows the NASDAQ Biotechnology Index. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
A2DWAW invests in stocks.